- Home
- BITF vs UPB Comparison
BITF vs UPB Comparison
Compare BITF & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BITF
- UPB
- Stock Information
- Founded
- BITF 2017
- UPB 2021
- Country
- BITF Canada
- UPB United States
- Employees
- BITF N/A
- UPB N/A
- Industry
- BITF Finance: Consumer Services
- UPB
- Sector
- BITF Finance
- UPB
- Exchange
- BITF Nasdaq
- UPB NYSE
- Market Cap
- BITF 564.7M
- UPB 521.3M
- IPO Year
- BITF N/A
- UPB 2024
- Fundamental
- Price
- BITF $1.07
- UPB $11.49
- Analyst Decision
- BITF Strong Buy
- UPB Strong Buy
- Analyst Count
- BITF 3
- UPB 4
- Target Price
- BITF $4.83
- UPB $56.50
- AVG Volume (30 Days)
- BITF 16.7M
- UPB 496.2K
- Earning Date
- BITF 08-07-2025
- UPB 08-14-2025
- Dividend Yield
- BITF N/A
- UPB N/A
- EPS Growth
- BITF N/A
- UPB N/A
- EPS
- BITF N/A
- UPB N/A
- Revenue
- BITF $209,412,000.00
- UPB $2,296,000.00
- Revenue This Year
- BITF $88.01
- UPB N/A
- Revenue Next Year
- BITF $84.80
- UPB N/A
- P/E Ratio
- BITF N/A
- UPB N/A
- Revenue Growth
- BITF 25.67
- UPB N/A
- 52 Week Low
- BITF $0.67
- UPB $5.14
- 52 Week High
- BITF $3.15
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- BITF 66.37
- UPB N/A
- Support Level
- BITF $0.98
- UPB N/A
- Resistance Level
- BITF $1.09
- UPB N/A
- Average True Range (ATR)
- BITF 0.08
- UPB 0.00
- MACD
- BITF 0.03
- UPB 0.00
- Stochastic Oscillator
- BITF 82.22
- UPB 0.00
About BITF Bitfarms Ltd.
Bitfarms Ltd engaged in the cryptocurrency Mining industry mainly consists of selling its computational power used for hashing calculations for cryptocurrency mining in multiple jurisdictions. Its geographic operations are currently located in Canada, the United States, Argentina. It owns and operates server farms comprised of computers designed to validate transactions on the Bitcoin Blockchain.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.